Premium
Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database
Author(s) -
Florek A.G.,
Nardone B.,
Thareja S.,
Tran G.,
Giles F.J.,
West D.P.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15752
Subject(s) - ustekinumab , pharmacovigilance , medicine , food and drug administration , adverse event reporting system , adverse effect , european union , drug , secukinumab , ixekizumab , pharmacology , marketing authorization , adverse drug reaction , psoriasis , database , immunology , bioinformatics , business , adalimumab , disease , computer science , economic policy , psoriatic arthritis , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom